Recent innovations in the management of low-grade gliomas

Shaheryar Hafeez; Robert Cavaliere

doi:10.1007/s11940-012-0185-6

Recent innovations in the management of low-grade gliomas

Shaheryar Hafeez, Robert Cavaliere

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Advancement in the understanding of biologic mechanisms of low-grade glioma pathophysiology has allowed the modern era of patient-specific genetic profiling, molecular biology, and neuroimaging to design new methods of surgery, radiation, and chemotherapy in hopes of preventing malignant transformation and improving outcomes. Recent innovations in the understanding of MGMT promoter methylation, IDH1 and IDH2 mutations, temozolomide chemotherapy, vascular monoclonal antibody treatment, use of radiation therapy, choice of antiepileptic drugs, surgical resection, and neuroimaging of lowgrade gliomas are reviewed.

Original language	English (US)
Pages (from-to)	369-380
Number of pages	12
Journal	Current Treatment Options in Neurology
Volume	14
Issue number	4
DOIs	https://doi.org/10.1007/s11940-012-0185-6
State	Published - Aug 2012
Externally published	Yes

Keywords

1p/19q deletion
Chemotherapy
Clinical trials
IDH1 mutation
IDH2 mutation
Low-grade glioma
PCV
Prognostic factors
Progression-free survival
Surgery
Survival
TMZ
Treatment
Vaccination

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1007/s11940-012-0185-6

Fingerprint Dive into the research topics of 'Recent innovations in the management of low-grade gliomas'. Together they form a unique fingerprint.

Cite this

@article{43ab57556b9641b49e74e274df077a32,

title = "Recent innovations in the management of low-grade gliomas",

abstract = "Advancement in the understanding of biologic mechanisms of low-grade glioma pathophysiology has allowed the modern era of patient-specific genetic profiling, molecular biology, and neuroimaging to design new methods of surgery, radiation, and chemotherapy in hopes of preventing malignant transformation and improving outcomes. Recent innovations in the understanding of MGMT promoter methylation, IDH1 and IDH2 mutations, temozolomide chemotherapy, vascular monoclonal antibody treatment, use of radiation therapy, choice of antiepileptic drugs, surgical resection, and neuroimaging of lowgrade gliomas are reviewed.",

keywords = "1p/19q deletion, Chemotherapy, Clinical trials, IDH1 mutation, IDH2 mutation, Low-grade glioma, PCV, Prognostic factors, Progression-free survival, Surgery, Survival, TMZ, Treatment, Vaccination",

author = "Shaheryar Hafeez and Robert Cavaliere",

year = "2012",

month = aug,

doi = "10.1007/s11940-012-0185-6",

language = "English (US)",

volume = "14",

pages = "369--380",

journal = "Current Treatment Options in Neurology",

issn = "1092-8480",

publisher = "Current Science, Inc.",

number = "4",

}

TY - JOUR

T1 - Recent innovations in the management of low-grade gliomas

AU - Hafeez, Shaheryar

AU - Cavaliere, Robert

PY - 2012/8

Y1 - 2012/8

N2 - Advancement in the understanding of biologic mechanisms of low-grade glioma pathophysiology has allowed the modern era of patient-specific genetic profiling, molecular biology, and neuroimaging to design new methods of surgery, radiation, and chemotherapy in hopes of preventing malignant transformation and improving outcomes. Recent innovations in the understanding of MGMT promoter methylation, IDH1 and IDH2 mutations, temozolomide chemotherapy, vascular monoclonal antibody treatment, use of radiation therapy, choice of antiepileptic drugs, surgical resection, and neuroimaging of lowgrade gliomas are reviewed.

AB - Advancement in the understanding of biologic mechanisms of low-grade glioma pathophysiology has allowed the modern era of patient-specific genetic profiling, molecular biology, and neuroimaging to design new methods of surgery, radiation, and chemotherapy in hopes of preventing malignant transformation and improving outcomes. Recent innovations in the understanding of MGMT promoter methylation, IDH1 and IDH2 mutations, temozolomide chemotherapy, vascular monoclonal antibody treatment, use of radiation therapy, choice of antiepileptic drugs, surgical resection, and neuroimaging of lowgrade gliomas are reviewed.

KW - 1p/19q deletion

KW - Chemotherapy

KW - Clinical trials

KW - IDH1 mutation

KW - IDH2 mutation

KW - Low-grade glioma

KW - PCV

KW - Prognostic factors

KW - Progression-free survival

KW - Surgery

KW - Survival

KW - TMZ

KW - Treatment

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84865863354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865863354&partnerID=8YFLogxK

U2 - 10.1007/s11940-012-0185-6

DO - 10.1007/s11940-012-0185-6

M3 - Article

C2 - 22798081

AN - SCOPUS:84865863354

VL - 14

SP - 369

EP - 380

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 4

ER -

Recent innovations in the management of low-grade gliomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this